Carl Zeiss Meditec leads structurally, with valuation as the clearest single gap between the two profiles. Corcept Therapeutics still leads on growth and stability, which keeps the comparison from looking entirely one-sided. In the market, Corcept Therapeutics carries the stronger setup — intact trend against Carl Zeiss Meditec's broken trend. That leaves a split case: the structural lead stays with Carl Zeiss Meditec, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (AFX.DE: HDAX, CORT: Russell 1000).
Most of the separation is still concentrated in valuation. The overall score gap is 9 points in favour of Carl Zeiss Meditec AG.
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.
Most of the shared profile comes through capital structure and operating margin level.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Pricing shapes this comparison more than a broad operating gap.
Left means cheaper relative valuation. Higher means stronger structure.
Corcept Therapeutics Incorporated occupies the cheaper side of the setup map, although Carl Zeiss Meditec AG still holds the stronger structural profile.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where AFX.DE and CORT each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a forward P/E that is 5.5 turns lower.
Corcept Therapeutics still pushes back on growth, with a 29-point revenue-growth advantage that keeps the read from becoming one-way.
The valuation lead is clear, but pricing and growth still pull in the other direction — the result holds, but not without friction.
Break down the AFX.DE vs CORT comparison across all dimensions with the full interactive tool.
Explore how AFX.DE and CORT each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.